Amarin Corporation plc

NASDAQ:AMRN

Biotechnology

Healthcare
$11.26 +1.84%

+$0.29 today

Market cap
$232.89M
Beta
0.82
P/E (TTM)
-9.9
EPS (TTM)
-$1.62
52W Low $12.30High $20.90

Volume 0.09M

Average 0.07M

AMRN Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Amarin Corporation plcNASDAQ: AMRN

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $638K fell 12.6% year over year, behind the -1.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 9.0% from the prior quarter. Over 3 fiscal years it compounded at -0.7% a year.

Context

  • Depreciation & amortization amounted to 1.4% of revenue in FY2025, unchanged from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -12.6% toward the trailing-twelve-month pace of -1.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$638K-9.0% QoQ
Last fiscal yearDec 2025
$3.03M+0.5% YoY
LTMMar 2026
$2.93M-1.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.6%——
1 year+0.5%——
3-year CAGR-0.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
3.03M USD
Year-over-year change
+0.5%
4-year CAGR
+1.5%

Depreciation & Amortization vs competitors

How AMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -1.6% is the 5th highest of 10, against a peer median of -2.6%.
  • Depreciation & amortization amounts to 1.4% of revenue for AMRN, versus a peer median of 76.1%.
AMRN Competitors
Depreciation & Amortization for AMRN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLLSCellectis S.A.LTM Mar 2026$19.68M USD-2.6%+2.9%28.9%
DBVTDBV Technologies S.A.LTM Mar 2026$12.36M USD+53.3%-27.5%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$10.43M USD-42.2%-13.8%33645.2%
KRROKorro Bio, Inc.LTM Mar 2026$3.44M USD-15.5%+19.5%89.4%
AMRNAmarin Corporation plcLTM Mar 2026$2.93M USD-1.6%-0.7%1.4%
ACIUAC Immune S.A.LTM Mar 2026CHF 1.61M CHF-27.3%+2.0%43.6%
ENGNenGene Holdings Inc.LTM Apr 2026$670K USD+79.6%+28.8%—
ANROAlto Neuroscience, Inc.LTM Mar 2026$605K USD+5.0%+24.6%—
SLNSilence Therapeutics plcLTM Mar 2026$577.79K USD—+4.5%62.7%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$326K USD+0.0%+3.2%—
ALTAltimmune, Inc.LTM Mar 2026$106K USD-33.8%-39.0%294.4%
Peer median (excluding AMRN) —-2.6%+3.1%76.1%

Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue583.19M369.19M306.91M228.61M213.65M
Cost of Revenue121.33M126.71M141.37M147.23M92.78M
Gross Profit461.86M242.48M165.54M81.38M120.87M
Gross Margin79.2%65.7%53.9%35.6%56.6%
Research & Development29.31M30.41M22.22M20.87M19.81M
Selling, General & Admin408.33M304.42M199.94M152.31M115M
Operating Expenses451.36M348.35M222.16M173.18M134.81M
Depreciation & Amortization2.86M3.1M2.97M3.01M3.03M
EBITDA14.28M(100.69M)(50.7M)(74.18M)(33.01M)
EBITDA Margin2.4%-27.3%-16.5%-32.4%-15.5%
Operating Income10.5M(105.87M)(56.62M)(91.8M)(13.94M)
Operating Margin1.8%-28.7%-18.4%-40.2%-6.5%
Interest Income1.22M2.82M11.86M13.4M10.85M
Interest Expense129K15K8K7K7K
Other Income / Expenses789K2.06M2.95M14.6M(22.11M)
Income Before Tax11.29M(103.81M)(53.67M)(77.2M)(36.05M)
Pre-Tax Margin1.9%-28.1%-17.5%-33.8%-16.9%
Income Tax Expense3.56M2M5.44M4.98M2.75M
Net Income7.73M(105.8M)(59.11M)(82.18M)(38.8M)
Net Margin1.3%-28.7%-19.3%-35.9%-18.2%
EPS (Basic)0.39(5.20)(3.00)(4.00)(1.80)
EPS (Diluted)0.38(5.20)(3.00)(4.00)(1.80)
Weighted Avg Shares19.8M20.06M19.7M20.55M20.75M
Weighted Avg Shares (Diluted)20.12M20.06M20.38M20.55M20.75M

Amarin Corporation plc

NASDAQ:AMRN

Intrinsic Alpha fair value

Locked

Current Price

$11.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.